BGB324 markedly reduced p-STAT3 activity in BL PDAC cells, switched BL tumors toward a more differentiated CLA-like phenotype, and reduced the expression of stromal IL-6, particularly when combined with gemcitabine. The gene discussed is STAT3; the disease is Burkitt lymphoma.